Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: Association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest

British Journal of Cancer

Volumn 77, Issue 3, 1998, Pages 404-411

  Roth, W ^a   Wagenknecht, B ^a   Grimmel, C ^a   Dichgans, J ^a   Weller, M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

bcl 2; CD95 (Fas APO 1); Malignant glioma; p53; Synergy; Taxol

Indexed keywords

FAS LIGAND; PACLITAXEL; PHOSPHOSERINE; PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOTOXICITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE;

EID: 0031973358     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.64     Document Type: Article

References (43)

1. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 269-335
2. Berkova N and Pagé M (1995) Addition of hTNF-alpha potentiates cytotoxicity of Taxol in human ovarian cancer lines. Anticancer Res 15: 863-866
3. Bhalla K, Ibrado AM, Tourkina E, Tang C, Maloney ME and Huang Y (1993) Taxol induces internucleosomal DNA fragmentation associated with programmed cell death in human myeloid leukemia cells. Leukemia 7: 563-568
4. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J and Neckers L (1995) Taxol induction of p21 waf1 and p53 requires c-raf-1. Cancer Res 55: 4623-4626
5. Blagosklonny MV, Schulte T, Nguyen P, Trepel J and Neckers LM (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: 1851-1854
6. Cahan MA, Walter KA, Colvin OM and Brem H (1994) Cytotoxicity of taxol in vitro against human and rat malignant brain tumors. Cancer Chemother Pharmacol 33: 441-444
7. Chamberlain MC and Kormanik P (1995) Salvage chemotherapy with paclitaxel for recurrent primary brain tumors. J Clin Oncol 13: 2066-2071
8. Ding AH, Porteu F, Sanchez E and Nathan CF (1990) Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science 248: 370-372
9. Fujisawa K, Asahara H, Okamoto K, Aono H, Hasunuma T, Kobata T, Iwakura Y, Yonehara S, Sumida T and Nishioka K (1996) Therapeutic effect of the anti-fas antibody on arthritis in HTLV-1 tax transgenic mice. J Clin Invest 98: 271-278
10. Glantz MJ, Choy H, Kearns CM, Akerley W and Egorin MJ (1995a) Weekly, outpatient paclitaxel and concurrent cranial irradiation in adults with brain tumors: preliminary results and promising directions. Semin Oncol 22(suppl. 12): 26-32
11. Giantz MJ, Choy H, Kearns CM, Mills PC, Wahlberg LU, Zuhowski EG, Calabresi P and Egorin MJ (1995b) Paclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumors. J Natl Cancer Inst 87: 1077-1081
12. Haldar S, Jena N and Croce CM (1995) Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511
13. Haldar S, Chintapalli J and Croce CM (1996) Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255
14. Heimans JJ, Vermorken JB, Wolbers JG, Eeltink CM, Meijer OWM, Taphoorn MJB and Beijnen JH (1994) Paclitaxel (taxol) concentrations in brain tumor tissue. Ann Oncol 5: 951-953
15. Helson L, Helson C, Malik S, Ainsworth S and Mangiardi J (1993) A saturation threshold for taxol cytotoxicity in human glial and neuroblastoma cells. Anticancer Drug 4: 487-490
16. Horwitz SB, Lothstein L, Manfredi J, Mellado W, Parness J, Roy SN, Schiff PB, Sorbara L and Zeheb R (1986) Taxol: mechanisms of action and resistance. Ann NY Acad Sci 466: 733-744
17. Milross CG, Mason KA, Hunter NR, Chung WK, Peters LJ and Milas L (1996) Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel. J Natl Cancer Inst 88: 1308-1314
18. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T and Nagata S (1993) Lethal effect of the anti-Fas antibody in mice. Nature 364: 806-809
19. Oltvai ZN, Milliman CL and Korsmeyer SJ (1993) Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619
20. Prados MD, Schold SC, Spence AM, Berger MS, McAllister LD, Mehta MP, Gilbert R, Fulton D, Kuhn J, Lamborn K, Rector DJ and Chang SM (1996) Phase II study of paclitaxel in patients with recurrent malignant glioma. J Clin Oncol 14: 2316-2321
21. Rensing-Ehl A, Frei K, Flury R, Matiba B, Mariani SM, Weller M, Aebischer P, Krammer PH and Fontana A (1995) Loco-regional Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol 25: 2253-2258
22. Riondel J, Jacrot M, Fessi H, Puisieux F and Potier (1992) Effects of free and liposome-encapsulated taxol on two brain tumors xenografted into nude mice. In Vivo 6: 23-27
23. Roth W, Fontana A, Trepel M, Reed JC, Dichgans J and Weller M (1997) Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics. Cancer Immunol Immunother 44: 55-63
24. Rowinsky EK, Donehower RC, Jones RJ and Tucker RW (1988) Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res 48: 4093-4100
25. Sato K, Kimura F, Nakamura Y, Murakami H, Yoshida M, Tanaka M, Nagata S, Kanatani Y, Wakimoto N, Nagata N and Motoyoshi K (1996) An aggressive nasal lymphoma accompanied by high levels of soluble Fas ligand. Br J Haematol 94: 379-382
26. Schiff PB, Fant J and Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277: 665-667
27. Silbergeld DL, Chicoine MR and Madsen CL (1995) In vitro assessment of Taxol for human glioblastoma: chemosensitivity and cellular locomotion. Anticancer Drug 6: 270-276
28. waf1/cip1. Br J Cancer 74(suppl. 27): S82-S85
29. Tishler RB, Geard CR, Hall EJ and Schiff PB (1992) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 52: 3495-3497
30. Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJS, Friedmann T, De Tribolet N and Cavenee WK (1994) Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res 54: 649-652
31. Wahl AF, Donaldson KL, Fairchild C, Lee FYF, Foster SA, Demers GW and Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Med 2: 72-79
32. Waldman T, Kinzler KW and Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55: 5187-5190
33. Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC, Domb A and Brem H (1994) Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54: 2207-2212
34. Webb JL (1963) Effect of more than one inhibitor. In Enzyme and Metabolic Inhibitors. Vol. 1, pp. 66-79, 487-512. Academic Press: New York
35. Weller M (1996) Genetic regulation and therapeutic modulation of apoptosis in human malignant glioma. Cell Physiol Biochem 6: 376-380
36. Weller M and Fontana A (1995) The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T cell apoptosis, and the immune privilege of the brain. Brain Res Rev 21: 128-151
37. Weller M, Frei K, Groscurth P, Krammer PH, Yonekawa Y and Fontana A (1994) Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. J Clin Invest 94: 954-964
38. Weller M, Frei K, Malipiero U, Groscurth P, Yonekawa Y, Krammer P and Fontana A (1995a) Fas/APO-1-mediated apoptosis of human malignant glioma. Neurology 45(suppl. 4): A401, 859S
39. Weller M, Malipiero U, Aguzzi A, Reed JC and Fontana A (1995b). Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643
40. Weller M, Malipiero U, Rensing-Ehl A, Barr P and Fontana A (1995c) Fas/APO-1 gene transfer for human malignant glioma. Cancer Res 55: 2936-2944
41. Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S and Reed JC (1997) Hypericin-induced apoptosis of human malignant glioma cells is light dependent, independent of bcl-2 expression and does not require wild type p53. Neurol Res 19: 459-170
42. Williams S, Mutch DG, Xu L and Collins JL (1992) Divergent effects of taxol on tumor necrosis factor-alpha-mediated cytolysis of ovarian carcinoma cells. Am J Obstet Gynecol 167: 1870-1876
43. Zuber P, Accolla RS, Carrel S, Diserens AC and De Tribolet N (1988) Effects of recombinant human tumor necrosis factor-alpha-α on the surface phenotype and the growth of human malignant glioma cell lines. Int J Cancer 42: 780-786